Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KarT (Bristol Myers Squibb)
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KarT is an investigational small molecule oral combination prototype being developed by Bristol Myers Squibb. It is a novel formulation within the KarXT (xanomeline-trospium) family, which acts as a first-in-class dual agonist of the M1 and M4 muscarinic acetylcholine receptors. Unlike traditional antipsychotics that primarily target dopamine receptors, KarT aims to treat neuropsychiatric symptoms by modulating cholinergic signaling. The drug is currently being evaluated in Phase 1 pharmacokinetic studies to compare its profile against the reference drug KarXT (marketed as Cobenfy) and other prototypes. Its development is particularly focused on pediatric neuropsychiatry, including the treatment of irritability associated with autism spectrum disorder.
- Other names
- xanomeline + trospium chloride
02
Targets
CHRM4 (M4)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on KarT (Bristol Myers Squibb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KarT (Bristol Myers Squibb).